DE60019321D1 - Verfahren zum screening von inhibitoren von asp2 - Google Patents
Verfahren zum screening von inhibitoren von asp2Info
- Publication number
- DE60019321D1 DE60019321D1 DE60019321T DE60019321T DE60019321D1 DE 60019321 D1 DE60019321 D1 DE 60019321D1 DE 60019321 T DE60019321 T DE 60019321T DE 60019321 T DE60019321 T DE 60019321T DE 60019321 D1 DE60019321 D1 DE 60019321D1
- Authority
- DE
- Germany
- Prior art keywords
- cleavage
- asp
- compounds
- substrate
- asp2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96472—Aspartic endopeptidases (3.4.23)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9924957 | 1999-10-21 | ||
GBGB9924957.5A GB9924957D0 (en) | 1999-10-21 | 1999-10-21 | Novel treatment |
PCT/GB2000/004039 WO2001029563A1 (en) | 1999-10-21 | 2000-10-19 | Method of screening for inhibitors of asp2 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60019321D1 true DE60019321D1 (de) | 2005-05-12 |
DE60019321T2 DE60019321T2 (de) | 2005-09-08 |
Family
ID=10863153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60019321T Expired - Fee Related DE60019321T2 (de) | 1999-10-21 | 2000-10-19 | Verfahren zum screening von inhibitoren von asp2 |
Country Status (9)
Country | Link |
---|---|
US (2) | US20050277165A1 (de) |
EP (1) | EP1224469B1 (de) |
JP (1) | JP2003512043A (de) |
AT (1) | ATE292801T1 (de) |
AU (1) | AU7934900A (de) |
DE (1) | DE60019321T2 (de) |
ES (1) | ES2240183T3 (de) |
GB (1) | GB9924957D0 (de) |
WO (1) | WO2001029563A1 (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9701684D0 (en) | 1997-01-28 | 1997-03-19 | Smithkline Beecham Plc | Novel compounds |
TR200101484T2 (tr) | 1998-09-24 | 2002-06-21 | Pharmacia&Upjohn Company | Alzheimer hastalığı sekretazı |
US6699671B1 (en) | 1998-09-24 | 2004-03-02 | Pharmacia & Upjohn Company | Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
US6844148B1 (en) | 1998-09-24 | 2005-01-18 | Pharmacia & Upjohn Company | Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
US7456007B1 (en) | 1998-12-31 | 2008-11-25 | Elan Pharmaceuticals, Inc. | β-secretase enzyme compositions and methods |
US7115410B1 (en) | 1999-02-10 | 2006-10-03 | Elan Pharmaceuticals, Inc. | β-secretase enzyme compositions and methods |
JP4653318B2 (ja) | 1999-02-10 | 2011-03-16 | エラン ファーマシューティカルズ,インコーポレイテッド | βセクレターゼ酵素組成物および方法 |
US7514408B1 (en) | 1999-12-02 | 2009-04-07 | Elan Pharmaceuticals, Inc. | β-secretase enzyme compositions and methods |
ATE343562T1 (de) | 2000-03-23 | 2006-11-15 | Elan Pharm Inc | Verbindungen und verfahren zur behandlung der alzheimerschen krankheit |
CA2464736A1 (en) * | 2001-10-23 | 2003-05-15 | Oklahoma Medical Research Foundation | Beta-secretase inhibitors and methods of use |
TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
EP2281824A1 (de) | 2009-08-07 | 2011-02-09 | Noscira, S.A. | Furan-Imidazolon-Derivate zur Behandlung von kognitiven, neurodegenerativen oder neuronalen Erkrankungen oder Funktionsstörungen |
TW201300417A (zh) | 2010-11-10 | 2013-01-01 | Genentech Inc | 用於神經疾病免疫療法之方法及組合物 |
WO2012069428A1 (en) | 2010-11-22 | 2012-05-31 | Noscira, S.A. | Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions |
JP2013158281A (ja) * | 2012-02-03 | 2013-08-19 | Shionogi & Co Ltd | 新規bace1活性測定方法 |
ES2703598T3 (es) | 2013-06-12 | 2019-03-11 | Merck Patent Gmbh | Derivados de hidroxietileno para el tratamiento de la artrosis |
WO2016081640A1 (en) | 2014-11-19 | 2016-05-26 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
EP3221364B1 (de) | 2014-11-19 | 2020-12-16 | Genentech, Inc. | Antikörper gegen bace1 und deren verwendung zur immuntherapie von nervenerkrankungen |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5187153A (en) * | 1986-11-17 | 1993-02-16 | Scios Nova Inc. | Methods of treatment using Alzheimer's amyloid polypeptide derivatives |
US4963654A (en) * | 1989-02-13 | 1990-10-16 | Taisho Pharmaceutical Co., Ltd. | Peptide serine protease inhibitor |
US5292652A (en) * | 1990-10-05 | 1994-03-08 | Athena Neurosciences, Inc. | Amyloidin protease and uses thereof |
WO1995013084A1 (en) * | 1992-05-11 | 1995-05-18 | Miles Inc. | Cathepsin d is an amyloidogenic protease in alzheimer's disease |
WO1996040885A2 (en) * | 1995-06-07 | 1996-12-19 | Athena Neurosciences, Inc. | β-SECRETASE, ANTIBODIES TO β-SECRETASE, AND ASSAYS FOR DETECTING β-SECRETASE INHIBITION |
WO1998015828A1 (en) * | 1996-10-07 | 1998-04-16 | Scios Inc. | Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase |
GB9701684D0 (en) * | 1997-01-28 | 1997-03-19 | Smithkline Beecham Plc | Novel compounds |
US6699671B1 (en) * | 1998-09-24 | 2004-03-02 | Pharmacia & Upjohn Company | Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
US6313268B1 (en) * | 1998-10-16 | 2001-11-06 | Vivian Y. H. Hook | Secretases related to Alzheimer's dementia |
WO2001000663A2 (en) * | 1999-06-28 | 2001-01-04 | Oklahoma Medical Research Foundation | Catalytically active recombinant memapsin and methods of use thereof |
-
1999
- 1999-10-21 GB GBGB9924957.5A patent/GB9924957D0/en not_active Ceased
-
2000
- 2000-10-19 JP JP2001532104A patent/JP2003512043A/ja not_active Withdrawn
- 2000-10-19 AT AT00969693T patent/ATE292801T1/de not_active IP Right Cessation
- 2000-10-19 DE DE60019321T patent/DE60019321T2/de not_active Expired - Fee Related
- 2000-10-19 AU AU79349/00A patent/AU7934900A/en not_active Abandoned
- 2000-10-19 ES ES00969693T patent/ES2240183T3/es not_active Expired - Lifetime
- 2000-10-19 WO PCT/GB2000/004039 patent/WO2001029563A1/en active IP Right Grant
- 2000-10-19 EP EP00969693A patent/EP1224469B1/de not_active Expired - Lifetime
-
2003
- 2003-01-21 US US10/348,595 patent/US20050277165A1/en not_active Abandoned
-
2006
- 2006-07-14 US US11/486,738 patent/US20070021348A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20050277165A1 (en) | 2005-12-15 |
WO2001029563A1 (en) | 2001-04-26 |
GB9924957D0 (en) | 1999-12-22 |
ATE292801T1 (de) | 2005-04-15 |
EP1224469B1 (de) | 2005-04-06 |
US20070021348A1 (en) | 2007-01-25 |
AU7934900A (en) | 2001-04-30 |
EP1224469A1 (de) | 2002-07-24 |
JP2003512043A (ja) | 2003-04-02 |
ES2240183T3 (es) | 2005-10-16 |
DE60019321T2 (de) | 2005-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60019321D1 (de) | Verfahren zum screening von inhibitoren von asp2 | |
ATE224713T1 (de) | Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppression | |
NO20052928L (no) | Nye kjemiske forbindelser | |
DE69528475D1 (de) | Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie | |
ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
DE69427869D1 (de) | Botulinumtoxine zur behandlung von hyperhydrosis | |
DE69839815D1 (de) | Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten | |
NO20061736L (no) | Krystallform av epotilon B | |
DE59611411D1 (de) | Verwendung von alpha 1l-agonisten zur behandlung der harninkontinenz | |
ATE350030T1 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
DE60313434D1 (de) | Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen | |
DE60035693D1 (de) | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten | |
ATE173620T1 (de) | Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs | |
ATE225171T1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
DK1234025T3 (da) | Humane enzymer fra metalloproteasefamilien | |
BR9808923B1 (pt) | processos para fazer compostos inibidores de ciclooxigenase-2, e, compostos intermediÁrios para fazer inibidores de ciclooxigenase-2. | |
ATE289196T1 (de) | Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen | |
DE60144493D1 (de) | Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen | |
DE60130524D1 (de) | Verfahren zur elektrochemischen Behandlung von Artikeln | |
ATE283703T1 (de) | Neurodegenerative-erkrankung verwandtes gen | |
DE60010934D1 (de) | Medikamente geeignet zur Behandlung von proliferativen Erkrankungen | |
DE60119671D1 (de) | Verfahren zur Behandlung von Holzwerkstoff | |
ATE320255T1 (de) | Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen | |
DE60020591D1 (de) | Benzenoidderivate von 15-hydroxyeicosatetraensäure und verfahren zur verwendung zur behandlung des trockenen auges |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |